Business
Hardman Research: Ready for CTL019 approval
Hardman Research: Ready for CTL019 approval.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 9036O Oxford Biomedica PLC 24 August 2017 \n\nHardman Research: Ready for CTL019 approval\nReady for CTL019 approval - OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on commercial products developed with its LentiVector® platform. In the six months to end June 2017, Novartis made considerable progress towards approval of CTL019, improving sentiment for OXB which supplies vector essential for its manufacture. Post-period, a new deal was signed with Novartis, with OXB potentially receiving >$100m over three years. The cash position @31st July was £22.1m.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/24.08.17-ready-for-ctl019-approval.pdf\n\n\n\n\nTo contact us: \nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\n\n\nContacts:\nDr Martin Hall\[email protected] \nDr Dorothea Hill\[email protected] \nDr Gregoire Pave\[email protected]\nTelephone: +44 20 7194 7622\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the r...